GEMCITABINE VENUS 200 mg/1 bočica prašak za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

gemcitabine venus 200 mg/1 bočica prašak za rastvor za infuziju

corapharm d.o.o. - gemcitabin - prašak za rastvor za infuziju - 200 mg/1 bočica - 1 bočica sa praškom za rastvor za infuziju sadrži 200 mg gemcitabina (u obliku gemcitabinhidrohlorida)

GEMCITABINE VENUS 1000 mg/1 bočica prašak za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

gemcitabine venus 1000 mg/1 bočica prašak za rastvor za infuziju

corapharm d.o.o. - gemcitabin - prašak za rastvor za infuziju - 1000 mg/1 bočica - 1 bočica sa praškom za rastvor za infuziju sadrži 1000 mg gemcitabina (u obliku gemcitabinhidrohlorida)

PEMETREKSED LEK 500 mg/1 bočica prašak za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pemetreksed lek 500 mg/1 bočica prašak za rastvor za infuziju

novartis ba d.o.o. - pemetreksed - prašak za rastvor za infuziju - 500 mg/1 bočica - 1 bočica sa praškom za rastvor za infuziju sadrži: 500 mg pemetrekseda (u obliku pemetreksed dinatrija)

Imfinzi Europska Unija - hrvatski - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

GEMCITABIN Ebewe 10 mg/1 mL koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

gemcitabin ebewe 10 mg/1 ml koncentrat za rastvor za infuziju

novartis ba d.o.o. - gemcitabin - koncentrat za rastvor za infuziju - 10 mg/1 ml - 20 ml koncentrata za rastvor za infuziju sadrži: 200 mg gemcitabina (u obliku gemcitabinhidrohlorida)

GEMCITABIN Ebewe 10 mg/1 mL koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

gemcitabin ebewe 10 mg/1 ml koncentrat za rastvor za infuziju

novartis ba d.o.o. - gemcitabin - koncentrat za rastvor za infuziju - 10 mg/1 ml - 100 ml koncentrata za rastvor za infuziju sadrži: 1000 mg gemcitabina (u obliku gemcitabinhidrohlorida)

ERLOTINIB ACTAVIS 25 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

erlotinib actavis 25 mg/1 tableta film tableta

pliva d.o.o.sarajevo - erlotinib - film tableta - 25 mg/1 tableta - 1 film tableta sadrži: 25 mg erlotiniba (u obliku erlotinib hidrohlorida )

ERLOTINIB ACTAVIS 100 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

erlotinib actavis 100 mg/1 tableta film tableta

pliva d.o.o.sarajevo - erlotinib - film tableta - 100 mg/1 tableta - 1film tableta sadrži: 100mg erlotiniba (u obliku erlotinib hidrohlorida)

ERLOTINIB ACTAVIS 150 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

erlotinib actavis 150 mg/1 tableta film tableta

pliva d.o.o.sarajevo - erlotinib - film tableta - 150 mg/1 tableta - 1film tableta sadrži: 150 mg erlotiniba (u obliku erlotinib hidrohlorida)

Aybintio Europska Unija - hrvatski - EMA (European Medicines Agency)

aybintio

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).